„Arab Health“ 2024

Since its acquisition by Servona GmbH in 2014, Hoffrichter GmbH is part of the Orbisana Healthcare GmbH. Hoffrichter offers high quality respiration therapy and ventilation devices. New in our portfolio is a sleep diagnostic product (PG/PSG). With our innovative device, an individual therapy recommendation based on measured biosignals is ensured.

We show a clear focus on therapy reliability, patient safety and ease of use – all hallmarks of Hoffrichter GmbH since 1992.

All Hoffrichter systems can be used with minimal instruction, quickly and easily due to their simple and self-explanatory operation procedures. The devices are also extremely versatile by offering a wide range of ventilation modes, and can be adapted to suit the patient’s needs. Whether intended for domestic or clinical use, Hoffrichter ventilation devices offer the highest quality – „Made in Germany“.

Global Network

Operating at a global level, Orbisana Healthcare GmbH cooperates with many established companies in the fields of ventilation, respiratory therapy, tracheotomy and laryngectomy as well as incontinence care. Our high-quality medical devices, particularly those from our well-known brands HOFFRICHTER, SERVOX, SERVOCURA and SERVOVENT are exported all around the world from our German headquarters in Troisdorf and Hoffrichter premises in Schwerin.

IMAGE Information Systems develops customized and user-friendly solutions for radiological imaging. Satisfied users around the world benefit from state-of-the-art technology for PACS, RIS and teleradiology. Their home-grown iQ-SYSTEM PACS is used at more than 10,000 sites in more than 120 countries worldwide – both in small radiology practices as well as in large practice and hospital networks.

Plasmajet kINPen® MED – A disruptive technology to revolutionize the wound care market.

neoplas med GmbH neoplas med GmbH is an emerging young medical device company and world leader in the new and disruptive field of cold plasma jet-technology for accelerating wound healing. Its innovative product, the Argon cold plasma jet kINPen® MED, is the first internationally approved and marketed plasma jet for the treatment of pathogen-induced skin disorders and is MDR-certifed. The plasmajet kINPen® MED inactivates micro-organisms, stimulates micro-circulation and accelerates wound healing until possible wound closure, without any evidence of side effects and resistance development. 
neoplas med GmbH is a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany.

OR Technology has been successfully creating innovative and specialised X-ray solutions since 1991. OR Technology is a leading provider of digital X-ray imaging (CR, DR) and image management (PACS®). Its clients include hospitals, universities and specialised medical prac-tices as well as aid organisations, medical services and customers from the industry (NDT) and public authorities (security).

OR Technology’s know-how is based on decades of experience in developing software for digital image processing combined with specialised knowledge in the field of X-ray technolo-gy.

OR Technology is in a position to offer sophisticated and individually configurable system solutions to partners in medicine (human and vet) and industry.

OR Technology continuously invests in research and development, product design and cloud-based software tools through to automated reporting using artificial intelligence (AI).

PLUM Medical Solutions is a subsidiary company of IMAGE Information Systems Europe GmbH, based in Rostock, Germany, and was founded in 2017.

The company has developed "iQ-4CLOUD," a cloud-based PACS solution for radiology. This central image management system of PLUM Medical Solutions can process data from X-ray, ultrasound, computer tomography, magnetic resonance imaging, microscopy, endoscopy as well as PDF, video formats and other data. It allows viewing the diagnostic data on a smartphone, desk-top PC, tablet or laptop.

daisygrip is the first hygienically reusable venous tourniquet and has a unique intuitive locking system. With daisygrip, every routine blood sample is taken time-efficiently and under hygienic conditions, without changing current treatment procedures.

• Less germs: in-vitro-experiments show prevention of germ transport between patients (onsite disinfection)
• Significant cost savings: disposable tourniquets or infections caused by conventional tourniquets cause significantly higher costs than using daisygrip
• Reduced workload: the intuitive magnetic lock can be used quickly and reliably with one hand

We are facing a global hygiene challenge. Every year thousands of people die as a consequence of hospital-acquired infections. Our hands are the transmission path number 1. However, only every second hand disinfection is actually done. GWA Hygiene’s IoT-solution tracks all the hand hygiene events to motivate healthcare professionals and to optimise processes in the hospital. By doing so, every existing dispenser is upgraded with a sensor module. Moreover, every caregiver gets a badge that is attached to the clothes. Hence, the infection control team of the hospital gets insightful data regarding the disinfection behavior of different job groups (e.g. physicians, nurses). Statistics display e.g. which dispensers are used more often and which are used rarely. Consequently, the system provides notifications if thresholds are exceeded. Ultimately, the hand hygiene monitoring contributes to the reduction of infection rates.

Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP). The startup is located in Greifswald, Germany and has five employees. With the aim of providing comprehensive protection against infectious pathogens, the company develops application-oriented disinfection solutions that reliably kill not only bacteria and viruses but also persistent bacterial spores. Their patent pending disinfection process Sporosan^® is based on two starting components. When both components are mixed a strong and short-lived active agent is formed. Currently, the Nebula Biocides team is working on the medical device approval for washer disinfector applications. In the future, this will prevent infections with the dangerous hospital germ Clostridioides difficile, which leads to severe diarrhea and is often fatal, especially in previously ill patients.

We believe that movement is the source of satisfaction, and we are fully committed to maintaining people's mobility. We do this by thinking preventively and inventing technically sophisticated solutions. Our products integrate seamlessly into everyday life to prevent ulcers and wounds.

osentec - don't worry, keep moving

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald. The aspiring company develops products for medical applications based on plasma medicine research to meet patient’s needs. The first milestone is the CE-marked atmospheric pressure plasmajet kINPen^® MED, which can be used for a wide range of acute and chronic wound indications as well as pathogen-related skin diseases.

Plasma is not the same – our unique benefits

• High precision handling without contact to the wound and under visual control also in anatomically and pathologically demanding areas
• 3-fold working principle:

1. Effective inactivation of bacteria, fungi and viruses (including multi-resistant germs such as MRSA)
2. Promotion of the microcirculation, thereby improving the oxygen and nutrient supply of the tissue
3. Stimulation of the growth and regeneration processes of the tissue until possible wound closure

• Targeted wounds treatments: surgical side infections (SSI), complex and out of treatment wounds, chronic wounds
• No side effects and resistance formation
• Consistent plasma quality with every treatment through argon gas
• Easy to use, delegable to trained professional user

In terms of clinical effectiveness, the kINPen^® MED is the world’s best evidence proven medical plasma device. Recently, it has been published the first placebo-controlled clinical trial. The results prove the successful application in diabetic foot ulcers resulting in reactivation and acceleration of wound healing (JAMA Network Open, Stratmann et al)

Please contact us at contact{at}neoplas-med.eu.